Electroconvulsive therapy suppresses the neurotoxic branch of the kynurenine pathway in treatment-resistant depressed patients

Journal of Neuroinflammation

Volumn 13, Issue 1, 2016, Pages

  Schwieler, Lilly ^a   Samuelsson, Martin ^a,b   Frye, Mark A ^c   Bhat, Maria ^a,d   Schuppe Koistinen, Ina ^a,e   Jungholm, Oscar ^a   Johansson, Anette G ^a   Landén, Mikael ^a,f   Sellgren, Carl M ^a,g,h   Erhardt, Sophie ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c Mayo Clinic College of Medicine   (United States)

^d ASTRAZENECA R AND D   (Sweden)

^e SCIENCE FOR LIFE LABORATORY   (Sweden)

^f UNIVERSITY OF GOTHENBURG   (Sweden)

^g BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cytokines; ECT; IL 6; Inflammation; Kynurenic acid; NMDA receptor; Quinolinic acid; Treatment resistant depression

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BIOLOGICAL MARKER; CYTOKINE; HYPNOTIC AGENT; INTERLEUKIN 6; KYNURENINE; LITHIUM; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; QUINOLINIC ACID; TRYPTOPHAN; IL6 PROTEIN, HUMAN;

ADULT; AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; ELECTROCHEMICAL DETECTION; ELECTROCHEMILUMINESCENCE DETECTION; ELECTROCONVULSIVE THERAPY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR DEPRESSION; MALE; MASS SPECTROMETRY; METABOLITE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NEUROPATHOLOGY; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; THERAPY EFFECT; TREATMENT RESISTANT DEPRESSION; BLOOD; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; LUMINESCENCE; METABOLISM; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COHORT STUDIES; CYTOKINES; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; ELECTROCONVULSIVE THERAPY; FEMALE; HUMANS; INTERLEUKIN-6; KYNURENINE; LUMINESCENCE; MALE; METABOLIC NETWORKS AND PATHWAYS; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME; TRYPTOPHAN; YOUNG ADULT;

EID: 84978767426     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/s12974-016-0517-7     Document Type: Article

References (57)

1. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R) National Comorbidity Survey Replication. JAMA. 2003;289(23):3095-105.
2. WHO report (2014), Preventing suicide: a global imperative. http://apps.who.int/iris/bitstream/10665/131056/1/9789241564779_eng.pdf.
3. Murray CJ, Lopez AD. Measuring the global burden of disease. N Engl J Med. 2013;369(5):448-57.
4. Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annu Rev Public Health. 2013;3(34):119-38.
5. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9(1):46-56.
6. Leonard B, Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev. 2012;36(2):764-85.
7. Miller AH, Haroon E, Raison CL, Felger JC. Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depress Anxiety. 2013;30(4):297-306.
8. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446-57.
9. Valkanova V, Ebmeier KP, Allan CL. CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies. J Affect Disord. 2013;150(3):736-44.
10. Dahl J, Ormstad H, Aass HC, Malt UF, Bendz LT, Sandvik L, et al. The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery. Psychoneuroendocrinology. 2014;45:77-86.
11. Sasayama D, Hattori K, Wakabayashi C, Teraishi T, Hori H, Ota M, et al. Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder. J Psychiatr Res. 2013;47:401-6.
12. Lindqvist D, Janelidze S, Hagell P, Erhardt S, Samuelsson M, Minthon L, et al. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol Psychiatry. 2009;66(3):287-92.
13. Dantzer R, O'Connor JC, Lawson MA, Kelley KW. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology. 2011;36(3):426-36.
14. Erhardt S, Lim CK, Linderholm KR, Janelidze S, Lindqvist D, Samuelsson M, et al. Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacology. 2013;38(5):743-52.
15. Bay-Richter C, Linderholm KR, Lim CK, Samuelsson M, Träskman-Bendz L, Guillemin GJ, et al. A role for inflammatory metabolites as modulators of the glutamate N-methyl-D-aspartate receptor in depression and suicidality. Brain Behav Immun. 2015;43:110-7.
16. Myint AM, Kim YK. Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression. Med Hypotheses. 2003;61(5-6):519-25.
17. Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. 2003;13(7):465-77.
18. Guillemin GJ. Quinolinic acid, the inescapable neurotoxin. FEBS J. 2012;279(8):1356-65.
19. Kim H, Chen L, Lim G, Sung B, Wang S, McCabe MF, et al. Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression. J Clin Invest. 2012;122(8):2940-54.
20. Schwieler L, Larsson MK, Skogh E, Kegel ME, Orhan F, Abdelmoaty S, et al. Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia-significance for activation of the kynurenine pathway. J Psychiatry Neurosci. 2015;40(2):126-33.
21. Urata Y, Koga K, Hirota Y, Akiyama I, Izumi G, Takamura M, et al. IL-1β increases expression of tryptophan 2,3-dioxygenase and stimulates tryptophan catabolism in endometrioma stromal cells. Am J Reprod Immunol. 2014;72(5):496-503.
22. Erhardt S, Blennow K, Nordin C, Skogh E, Lindström LH, Engberg G. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett. 2001;313(1-2):96-8.
23. Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC. Increased cortical kynurenate content in schizophrenia. Biol Psychiatry. 2001;50(7):521-30.
24. Nilsson LK, Linderholm KR, Engberg G. Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res. 2005;80(2-3):315-22.
25. Miller CL, Llenos IC, Dulay JR. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res. 2006;16(1073-1074):25-37.
26. Olsson SK, Samuelsson M, Saetre P, Lindström L, Jönsson EG, Nordin C, et al. Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder. J Psychiatry Neurosci. 2010;35(3):195-9.
27. Sathyasaikumar KV, Stachowski EK, Wonodi I, Roberts RC, Rassoulpour A, McMahon RP, et al.: Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr Bull. 2011;37(6):1147-56.
28. Linderholm K, Skogh E, Olsson SK, Dahl ML, Holtze M, Engberg G, et al. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bul. 2012;38(3):426-32.
29. Steiner J, Walter M, Gos T, Guillemin GJ, Bernstein HG, Sarnyai Z, et al. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J Neuroinflammation. 2011;10(8):94.
30. Myint AM, Kim YK, Verkerk R, Scharpé S, Steinbusch H, Leonard B. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord. 2007;98(1-2):143-51.
31. Maes M, Galecki P, Verkerk R, Rief W. Somatization, but not depression, is characterized by disorders in the tryptophan catabolite (TRYCAT) pathway, indicating increased indoleamine 2,3-dioxygenase and lowered kynurenine aminotransferase activity. Neuro Endocrinol Lett. 2011;32(3):264-73.
32. Savitz J, Drevets WC, Smith CM, Victor TA, Wurfel BE, Bellgowan PS, et al. Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder. Neuropsychopharmacology. 2015;40(2):463-71.
33. Savitz J, Drevets WC, Wurfel BE, Ford BN, Bellgowan PS, Victor TA, et al. Reduction of kynurenic acid to quinolinic acid ratio in both the depressed and remitted phases of major depressive disorder. Brain Behav Immun. 2015;46:55-9.
34. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D. Report Am J Psychiatry. 2006;163(11):1905-17.
35. Katz MM, Tekell JL, Bowden CL, Brannan S, Houston JP, Berman N, et al. Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology. 2004;29(3):566-79.
36. Baldinger P, Lotan A, Frey R, Kasper S, Lerer B, Lanzenberger R. Neurotransmitters and electroconvulsive therapy. J ECT. 2014;30(2):116-21.
37. Haskett RF. Electroconvulsive therapy's mechanism of action: neuroendocrine hypotheses. J ECT. 2014;30(2):107-10.
38. Bouckaert F, Sienaert P, Obbels J, Dols A, Vandenbulcke M, Stek M, et al. ECT: its brain enabling effects: a review of electroconvulsive therapy-induced structural brain plasticity. J ECT. 2014;30(2):143-51.
39. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(20):22-33.
40. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-9.
41. First MB, Spitzer RI, Gibbon M, et al. Structured Clinical Interview for DMS-IV Axis I Disorders, Clinician Version (SCID-CV). Washington: American Psychiatric Press, inc; 1996.
42. Young JJ, Bruno D, Pomara N. A review of the relationship between proinflammatory cytokines and major depressive disorder. J Affect Disord. 2014;169(12):15-20.
43. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71(2):171-86.
44. Theofylaktopoulou D, Midttun Ø, Ulvik A, Ueland PM, Tell GS, Vollset SE, et al. A community-based study on determinants of circulating markers of cellular immune activation and kynurenines: the Hordaland Health Study. Clin Exp Immunol. 2013;173(1):121-30.
45. Deac OM, Mills JL, Shane B, Midttun Ø, Ueland PM, Brosnan JT, et al. Tryptophan catabolism and vitamin B-6 status are affected by gender and lifestyle factors in healthy young adults. J Nutr. 2015;145(4):701-7.
46. Claes S, Myint AM, Domschke K, Del-Favero J, Entrich K, Engelborghs S, et al. The kynurenine pathway in major depression: haplotype analysis of three related functional candidate genes. Psychiatry Res. 2011;188(3):355-60.
47. Guloksuz S, Arts B, Walter S, Drukker M, Rodriguez L, Myint AM, et al. The impact of electroconvulsive therapy on the tryptophan-kynurenine metabolic pathway. Brain Behav Immun. 2015;48:48-52.
48. DiazGranados N, Ibrahim LA, Brutsche NE, Ameli R, Henter ID, Luckenbaugh DA, et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry. 2010;71(12):1605-11.
49. Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2013;74(4):257-64.
50. Machado-Vieira R, Salvadore G, Diazgranados N, Zarate Jr CA. Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther. 2009;123(2):143-50.
51. Kirkegaard C, Møller SE, Bjørum N. Addition of L-tryptophan to electroconvulsive treatment in endogenous depression. A double-blind study. Acta Psychiatr Scand. 1978;58(5):457-62.
52. Mokhtar AS, Morgan CJ, Bradley DM, Badawy AA. No early effects of electroconvulsive therapy on tryptophan metabolism and disposition in endogenous depression. Biol Psychiatry. 1997;42(3):201-5.
53. Whalley LJ, Yates CM, Christie JE. Effect of electroconvulsive therapy (ECT) on plasma tryptophan. Psychol Med. 1998;10(2):377-80.
54. Palmio J, Huuhka M, Saransaari P, Oja SS, Peltola J, Leinonen E, et al. Changes in plasma amino acids after electroconvulsive therapy of depressed patients. Psychiatry Res. 2005;137(3):183-90.
55. Hoekstra R, van den Broek WW, Fekkes D, Bruijn JA, Mulder PG, Pepplinkhuizen L. Effect of electroconvulsive therapy on biopterin and large neutral amino acids in severe, medication-resistant depression. Psychiatry Res. 2001;103(2-3):115-23.
56. Okuno E, Kido R. Kynureninase and kynurenine 3-hydroxylase in mammalian tissues. Adv Exp Med Biol. 1991;294:167-76.
57. Bender DA, McCreanor GM. Kynurenine hydroxylase: a potential rate-limiting enzyme in tryptophan metabolism. Biochem Soc Trans. 1985;13(2):441-3.